Rapid Therapeutic Science Laboratories, Inc. (RTSL) Financial Statements (2025 and earlier)

Company Profile

Business Address 558 COUNTY ROAD 472
DE LEON, TX 76444
State of Incorp. NV
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
12/31/2021
Q4
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments17,572  112,16432,985192,484
Cash and cash equivalents17,572  112,16432,985192,484
Receivables      
Inventory, net of allowances, customer advances and progress billings175,047175,047175,047175,047175,048175,047
Inventory175,047175,047175,047175,047175,048175,047
Prepaid expense58,14658,14662,52066,89571,26951,631
Total current assets:250,765233,193237,567354,106279,302419,162
Noncurrent Assets
Operating lease, right-of-use asset318,878340,136361,395382,654403,912425,171
Property, plant and equipment1,294,7521,511,1761,517,1691,523,1611,838,2991,185,562
Intangible assets, net (including goodwill)170,075170,075170,075170,075170,075170,075
Intangible assets, net (excluding goodwill)170,075170,075170,075170,075170,075170,075
Total noncurrent assets:1,783,7052,021,3872,048,6392,075,8902,412,2861,780,808
TOTAL ASSETS:2,034,4702,254,5802,286,2062,429,9962,691,5882,199,970
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities148,907124,736205,696161,920123,17045,696
Interest and dividends payable102,84880,96061,58545,696
Accrued liabilities148,907124,736102,84880,96061,585 
Debt829,988820,6022,491,5762,229,4151,941,7621,099,734
Derivative instruments and hedges, liabilities80,520508,593569,5621,061,5641,162,4051,085,360
Due to related parties 744,800706,700683,700283,700
Other undisclosed current liabilities3,403,4233,511,897893,514700,9911,213,291538,493
Total current liabilities:4,462,8384,965,8284,905,1484,860,5905,124,3283,052,983
Noncurrent Liabilities
Long-term debt and lease obligation:   318,060338,542358,768378,744
Liabilities, other than long-term debt259,188280,235    
Operating lease, liability259,188280,235318,060338,542358,768378,744
Other undisclosed noncurrent liabilities150,000150,000(168,060)(188,542)(208,768)(228,744)
Total noncurrent liabilities:409,188430,235468,060488,542508,768150,000
Total liabilities:4,872,0265,396,0635,373,2085,349,1325,633,0963,581,727
Equity
Equity, attributable to parent(2,837,556)(3,141,483)(3,087,002)(2,919,136)(2,941,508)(1,381,757)
Common stock8,0827,7637,7477,7477,747193,567
Treasury stock, value(337,339)(337,339)(337,339)(337,339)(337,339)(337,339)
Additional paid in capital7,616,5797,504,2427,607,6787,548,4687,489,2587,283,438
Accumulated deficit(10,124,878)(10,316,149)(10,365,088)(10,138,012)(10,101,174)(8,521,423)
Total equity:(2,837,556)(3,141,483)(3,087,002)(2,919,136)(2,941,508)(1,381,757)
TOTAL LIABILITIES AND EQUITY:2,034,4702,254,5802,286,2062,429,9962,691,5882,199,970

Income Statement (P&L) (USD)

6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
12/31/2021
Q4
Revenues
(Other undisclosed Revenues)
      60
Gross profit:      60
Operating expenses(190,595)(3,099)(718,562)(229,499)(1,551,534)(1,216,610)
Operating loss:(190,595)(3,099)(718,562)(229,499)(1,551,534)(1,216,550)
Nonoperating income (expense)289,56521,597145,83191,537(790,358)(593,170)
Interest and debt expense(111,026)(70,576)(346,171)(765,590)(713,313)(654,317)
Loss from continuing operations before equity method investments, income taxes:(12,056)(52,078)(918,902)(903,552)(3,055,205)(2,464,037)
Other undisclosed income from continuing operations before income taxes203,327101,017691,826866,7141,475,4541,249,230
Income (loss) from continuing operations:191,27148,939(227,076)(36,838)(1,579,751)(1,214,807)
Loss before gain (loss) on sale of properties:(227,076)(36,838)(1,579,751)(1,214,807)
Net income (loss) available to common stockholders, diluted:191,27148,939(227,076)(36,838)(1,579,751)(1,214,807)

Comprehensive Income (USD)

6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
12/31/2021
Q4
Net income (loss):191,27148,939(227,076)(36,838)(1,579,751)(1,214,807)
Comprehensive income (loss), net of tax, attributable to parent:191,27148,939(227,076)(36,838)(1,579,751)(1,214,807)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: